Cited by 96Chemotherapy-related skin toxicityHair Growth and DisordersCancer Treatment and Pharmacology

A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention

Open access
Dunnill, Christopher John, Al-Tameemi, Wafaa, Collett, Andrew, Haslam, Iain Stuart, Georgopoulos, Nikolaos Theodoros·2018·The Oncologist

Abstract

Chemotherapy-induced alopecia (CIA) is the most visibly distressing side effect of commonly administered chemotherapeutic agents. Because psychological health has huge relevance to lifestyle, diet, and self-esteem, it is important for clinicians to fully appreciate the psychological burden that CIA can place on patients. Here, for the first time to our knowledge, we provide a comprehensive review encompassing the molecular characteristics of the human hair follicle (HF), how different anticancer agents damage the HF to cause CIA, and subsequent HF pathophysiology, and we assess known and emerging prevention modalities that have aimed to reduce or prevent CIA. We argue that, at present, scalp cooling is the only safe and U.S. Food and Drug Administration-cleared modality available, and we highlight the extensive available clinical and experimental (biological) evidence for its efficacy. The likelihood of a patient that uses scalp cooling during chemotherapy maintaining enough hair to not require a wig is approximately 50%. This is despite different types of chemotherapy regimens, patient-specific differences, and possible lack of staff experience in effectively delivering scalp cooling. The increased use of scalp cooling and an understanding of how to deliver it most effectively to patients has enormous potential to ease the psychological burden of CIA, until other, more efficacious, equally safe treatments become available. Implications for Practice: Chemotherapy-induced alopecia (CIA) represents perhaps the most distressing side effect of chemotherapeutic agents and is of huge concern to the majority of patients. Scalp cooling is currently the only safe option to combat CIA. Clinical and biological evidence suggests improvements can be made, including efficacy in delivering adequately low temperature to the scalp and patient-specific cap design. The increased use of scalp cooling, an understanding of how to deliver it most effectively, and biological evidence-based approaches to improve its efficacy have enormous potential to ease the psychological burden of CIA, as this could lead to improvements in treatment and patient quality-of-life.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2017-0263

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The hair follicle matrix is often targeted because it is more proliferatively active than malignant cells.

    “The hair follicle matrix is often targeted because it is more proliferatively active than malignant cells46.”

    From Morphological characteristics and notes of the skin in preclinical toxicity assessment (2023) · cites this paper as [46]

    Section 3.3 (p. 10) says hair-follicle matrix keratinocytes can divide faster than malignant cells, making them susceptible to chemotherapy. It does not establish that they are generally more proliferative or that the matrix is often targeted for that reason. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 134 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

  1. 15 Randall VA and Botchkareva NV: The biology of hair growth. Cosmetic applications of laser and light based systems: Elsevier Inc, 2008: 3-35.
  2. 68 Sredni B, Xu RH, Albeck M, et al. The protective role of the immunomodulator as101 against chemotherapy-induced alopecia studies on human and animal models. International journal of cancer 1996;65:97-103.
  3. 83 Davis ST, Benson BG, Bramson HN, et al. Prevention of chemotherapyinduced alopecia in rats by cdk inhibitors. Science 2001;291:134-137.
  4. 122 Payne S and Miles D. Mechanisms of anticancer drugs: CRC Press, 2008, 3446.
  5. 123 Trüeb RM: The difficult hair loss patient. Guide to successful management of alopecia and related conditions.: Springer International Publishing, 2015
  6. 125 Hussein AM, Jimenez JJ, McCall CA, et al. Protection from chemotherapyinduced alopecia in a rat model. Science 1990;249:1564-1566.

Cited by

Sorted by citations

Authors
Dunnill, C. J., Al-Tameemi, W., Collett, A., Haslam, I. S., & Georgopoulos, N. T.
Affiliations
University of Huddersfield (GB)
Corresponding author
Georgopoulos, Nikolaos Theodoros
Venue
The Oncologist
Published
2017-09-26
Volume
23
Issue
1
Pages
84-96
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2755791619
Cited by
96
References
134
Citations by year
2026: 10 · 2025: 14 · 2024: 15 · 2023: 10 · 2022: 13 · 2021: 12 · 2020: 13 · 2019: 5 · 2018: 3 · 2014: 1
FWCI
1.03
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • University of Huddersfield Repository (University of Huddersfield) (acceptedVersion)
  • SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University) (acceptedVersion)
  • Keele Research Repository (Keele University) (submittedVersion, cc-by)
  • Huddersfield Research Portal (University of Huddersfield) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
  • Health Sciences › Medicine › Urology › Hair Growth and Disorders
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
chemotherapy-induced alopecia, scalp cooling, hair follicle, anticancer drug toxicity, alopecia prevention, psychological burden, quality of life, cap design, hair loss
MeSH terms
Alopecia, Antineoplastic Agents, Humans, Hypothermia, Induced, Neoplasms, Prognosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review